Name | Type | Description | Interventions |
---|
Cohort A- Monotherapy in R/R lymphoma subjects | Experimental | Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles. | |
Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects | Experimental | Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.
Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.
Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2. | |
Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects | Experimental | Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.
Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6. | |
Cohort D - Monotherapy in other lymphomas subtype subjects | Experimental | Subjects with other lymphoma subtype who have been allocated to Cohort D will receive CC-220 monotherapy (MonoT).
- Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles. | |
Cohort E - CC-220 and rituximab in B-cell lymphoma subjects | Experimental | Subjects with aggressive B-cell lymphoma who have been allocated to Cohort E will receive CC-220 in combination with rituximab
Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2. | |
Cohort F - CC-220 and rituximab in FL and MZL subjects | Experimental | Subjects with follicular lymphoma (FL) (1 to 3a) and marginal zone lymphoma (MZL) who have been allocated to Cohort F Part 2 will receive CC-220 in combination with rituximab.
Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2 | |
Cohort G -CC-220 and obinutuzumab in FL and MZL subjects | Experimental | Subjects with FL (1 to 3a) and MZL who have been allocated to Cohort G will receive CC-220 in combination with obinutuzumab.
Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15 and on D1 of every 28-day cycle from C2 to C6. | |